Core Insights - Ascendis Pharma announced new data from the pivotal ApproaCH Trial, indicating that children with achondroplasia treated with TransCon CNP maintained consistent growth improvements through Week 104, with enhanced body proportionality observed in the second year of treatment [1][2]. Trial Results - The ApproaCH Trial involved 84 children aged 2-11 years, comparing TransCon CNP (100 µg/kg once-weekly) to placebo over 52 weeks, followed by an open-label extension to Week 104 [3]. - At Week 104, treatment with TransCon CNP showed a change in the upper-to-lower body segment ratio from -0.04 at Week 52 to -0.10 at Week 104, indicating continued improvement [7]. - Children switching from placebo to TransCon CNP at Week 52 exhibited similar improvements, with the upper-to-lower body segment ratio changing from -0.02 at Week 52 to -0.10 at Week 104 [7]. Safety and Tolerability - TransCon CNP was generally well-tolerated, with most adverse events being mild or moderate, and no treatment discontinuations reported [7]. - The overall rate of injection-site reactions was 0.35 per person-year of exposure, and there were no occurrences of symptomatic hypotension [7]. Regulatory Status - TransCon CNP received FDA approval in February 2026 under the trade name YUVIWEL for increasing linear growth in pediatric patients aged 2 years and older with achondroplasia [2]. - The Marketing Authorization Application for YUVIWEL is currently under review by the European Medicines Agency, with a decision expected in Q4 2026 [2]. Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform to address unmet medical needs [9].

Core Viewpoint - The conference call is focused on the FDA approval of YUVIWEL, highlighting its significance for Ascendis Pharma and its stakeholders [1]. Group 1: Company Overview - Chad Fugure serves as the Vice President of Investor Relations for Ascendis Pharma, leading the conference call [2]. - Key executives present include Jan Mikkelsen (President and CEO), Scott Smith (EVP and CFO), Jay Wu (EVP, President, U.S. Market), Aimee Shu (Chief Medical Officer), and Sherrie Glass (Chief Business Officer) [2]. Group 2: Conference Call Details - The call is being recorded, indicating a formal communication process for stakeholders [1]. - Forward-looking statements will be included in the discussion, suggesting a focus on future expectations and projections for the company [3].

Summary of Ascendis Pharma Conference Call Company Overview - **Company**: Ascendis Pharma (NasdaqGS:ASND) - **Product**: YUVIWEL, a treatment for achondroplasia - **FDA Approval**: YUVIWEL is the third FDA-approved drug from Ascendis Pharma, with plans for commercial launch in the U.S. in Q2 2026 [5][34] Key Points and Arguments FDA Approval and Product Details - YUVIWEL is the first and only once-weekly treatment for children with achondroplasia, utilizing TransCon technology to extend the half-life of C-type natriuretic peptide (CNP) from minutes to 5-6 days [6][7] - The FDA approval was based on data from three randomized double-blind placebo-controlled trials, including the pivotal ApproaCH Trial [7][8] - A Rare Pediatric Disease Priority Review Voucher was granted alongside the approval, allowing for priority review of a future drug application [8] Clinical Efficacy - In the pivotal ApproaCH Trial, children treated with YUVIWEL achieved an annualized growth velocity (AGV) of 5.9 cm/year compared to 4.4 cm/year for placebo, with a statistically significant treatment difference of 1.5 cm/year [20] - The treatment demonstrated improvements in height Z-scores across all predefined subgroups, including age, sex, and geographic region [21] Market Opportunity - The U.S. pediatric achondroplasia prevalence is estimated at around 2,600, with approximately 30% currently on pharmacological treatment [26] - There is a significant unmet need in the market, with many patients either not on treatment or having discontinued previous therapies due to tolerability or perceived lack of benefit [27] Commercial Strategy - Ascendis Pharma plans to engage with centers of excellence, thought leaders, and patient advocacy groups to educate stakeholders on YUVIWEL's clinical value proposition [28] - The company aims to optimize the patient experience and ensure affordability through programs that may allow eligible patients to pay as little as $0 a month [30] - Initial uptake is expected to come from both switches from existing therapies and treatment-naive patients [47] Future Plans - Ascendis Pharma has a roadmap to achieve $5 billion in product revenue by 2030, focusing on expanding the label for existing products and developing new therapies [14] - Plans include exploring indications for hypochondroplasia and adult patients with achondroplasia [70] Safety and Administration - YUVIWEL is designed to minimize injection site reactions and does not require food intake before administration, which is seen as a meaningful differentiation from existing therapies [22][55] - The product can be stored at room temperature for up to 6 months, enhancing convenience for patients [24] Additional Important Information - The company has a strong existing infrastructure from previous product launches, which will be leveraged for YUVIWEL [59] - Pricing for YUVIWEL has not yet been disclosed, but a premium pricing strategy is anticipated due to the product's differentiated benefits [45][46] - The company is prepared for potential reimbursement challenges and is engaging with payers to facilitate access [76] This summary encapsulates the critical aspects of the conference call, highlighting the company's strategic direction, product details, market potential, and future plans.